Skip to main content
SpringerLink
Log in

Psychopharmacology of Autism Spectrum Disorder

  • Chapter
  • First Online:
Interprofessional Care Coordination for Pediatric Autism Spectrum Disorder

Abstract

Increasingly, pharmacologic agents are used in treatment for children with ASD for related behaviors. This chapter describes trends in psychopharmacology related to ASD and the evidence base for its use in treatment. For each common medication group, mechanisms of action, possible symptom targets, adverse effects, and research base are discussed. The chapter then ends with recommendations for practitioners.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. (1999). Archives of General Psychiatry, 56(12), 1073–1086.

    Google Scholar 

  • Albertini, G., Polito, E., Sara, M., Di Gennaro, G., & Onorati, P. (2006). Compulsive masturbation in infantile autism treated by mirtazapine. Pediatric Neurology, 34(5), 417–418.

    PubMed  Google Scholar 

  • Allison, D. B., Basile, V. C., & MacDonald, R. B. (1991). Brief report: comparative effects of antecedent exercise and lorazepam on the aggressive behavior of an autistic man. Journal of Autism and Developmental Disorders, 21(1), 89–94.

    PubMed  Google Scholar 

  • Alvares, G. A., Quintana, D. S., & Whitehouse, A. J. (2017). Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder. Autism Research, 10(1), 25–41.

    PubMed  Google Scholar 

  • Aman, M. G. (1982). Stimulant drug effects in developmental disorders and hyperactivity–toward a resolution of disparate findings. Journal of Autism and Developmental Disorders, 12(4), 385–398.

    PubMed  Google Scholar 

  • Aman, M. G., Findling, R. L., Hardan, A. Y., Hendren, R. L., Melmed, R. D., Kehinde-Nelson, O., et al. (2017). Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension. Journal of Child and Adolescent zPsychopharmacology, 27(5), 403–412.

    Google Scholar 

  • Aman, M. G., Lam, K. S., & Van Bourgondien, M. E. (2005). Medication patterns in patients with autism: temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology, 15(1), 116–126.

    PubMed  Google Scholar 

  • Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., Research Units on Pediatric Psychopharmacology Autism, N. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1142–1154.

    Google Scholar 

  • Aman, M. G., Smith, T., Arnold, L. E., Corbett-Dick, P., Tumuluru, R., Hollway, J. A., et al. (2014). A review of atomoxetine effects in young people with developmental disabilities. Research in Developmental Disabilities, 35(6), 1412–1424.

    PubMed Central  PubMed  Google Scholar 

  • American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry, 65(2), 267–272.

    Google Scholar 

  • Anagnostou, E., Soorya, L., Chaplin, W., Bartz, J., Halpern, D., Wasserman, S., et al. (2012). Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Molecular Autism, 3(1), 16.

    PubMed Central  PubMed  Google Scholar 

  • Andari, E., Duhamel, J. R., Zalla, T., Herbrecht, E., Leboyer, M., & Sirigu, A. (2010). Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proceedings of the National Academy of Sciences, 107(9), 4389–4394.

    Google Scholar 

  • Andersen, I. M., Kaczmarska, J., McGrew, S. G., & Malow, B. A. (2008). Melatonin for insomnia in children with autism spectrum disorders. Journal of Child Neurology, 23(5), 482–485.

    PubMed  Google Scholar 

  • Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders, 19(2), 227–239.

    PubMed  Google Scholar 

  • Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. American Journal of Psychiatry, 141(10), 1195–1202.

    PubMed  Google Scholar 

  • Aoki, Y., Yahata, N., Watanabe, T., Takano, Y., Kawakubo, Y., Kuwabara, H., et al. (2014). Oxytocin improves behavioural and neural deficits in inferring others’ social emotions in autism. Brain, 137(Pt 11), 3073–3086.

    PubMed  Google Scholar 

  • Arnold, L. E., Aman, M. G., Cook, A. M., Witwer, A. N., Hall, K. L., Thompson, S., et al. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45(10), 1196–1205.

    PubMed  Google Scholar 

  • Barnard, L., Young, A. H., Pearson, J., Geddes, J., & O’Brien, G. (2002). A systematic review of the use of atypical antipsychotics in autism. Journal of Psychopharmacology, 16(1), 93–101.

    PubMed  Google Scholar 

  • Barrickman, L. L., Perry, P. J., Allen, A. J., Kuperman, S., Arndt, S. V., Herrmann, K. J., et al. (1995). Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 34(5), 649–657.

    PubMed  Google Scholar 

  • Beherec, L., Lambrey, S., Quilici, G., Rosier, A., Falissard, B., & Guillin, O. (2011). Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. Journal of Clinical Psychopharmacology, 31(3), 341–344.

    PubMed  Google Scholar 

  • Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 31(2), 175–181.

    PubMed  Google Scholar 

  • Bolognani, F., Del Valle Rubido, M., Squassante, L., Wandel, C., Derks, M., Murtagh, L., … Fontoura, P. (2019). A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine, 11(491).

    Google Scholar 

  • Bozkurt, H., & Mukaddes, N. M. (2010). Catatonia in a child with autistic disorder. Turkish Journal of Pediatrics, 52(4), 435–438.

    PubMed  Google Scholar 

  • Branford, D., Bhaumik, S., & Naik, B. (1998). Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. Journal of Intellectual Disabilities Research, 42(Pt 4), 301–306.

    Google Scholar 

  • Buchsbaum, M. S., Hollander, E., Haznedar, M. M., Tang, C., Spiegel-Cohen, J., Wei, T. C., et al. (2001). Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. International Journal of Neuropsychopharmacology, 4(2), 119–125.

    PubMed  Google Scholar 

  • Buitelaar, J. K., van der Gaag, R. J., & van der Hoeven, J. (1998). Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. Journal of Clinical Psychiatry, 59(2), 56–59.

    PubMed  Google Scholar 

  • Campbell, M. (1975). Pharmacotherapy in early infantile autism. Biological Psychiatry, 10(4), 399–423.

    PubMed  Google Scholar 

  • Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., et al. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17(4), 640–655.

    PubMed  Google Scholar 

  • Campbell, M., Anderson, L. T., Small, A. M., Locascio, J. J., Lynch, N. S., & Choroco, M. C. (1990). Naltrexone in autistic children: A double-blind and placebo-controlled study. Psychopharmacoly Bulletin, 26(1), 130–135.

    Google Scholar 

  • Campbell, M., Armenteros, J. L., Malone, R. P., Adams, P. B., Eisenberg, Z. W., & Overall, J. E. (1997). Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 36(6), 835–843.

    PubMed  Google Scholar 

  • Campbell, M., Fish, B., David, R., Shapiro, T., Collins, P., & Koh, C. (1972). Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. Journal of Autism and Childhood Schizophrenia, 2(4), 343–358.

    PubMed  Google Scholar 

  • Campbell, M., Small, A. M., Collins, P. J., Friedman, E., David, R., & Genieser, N. (1976). Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Current Therapeutic Research, Clinical & Experimental, 19(1), 70–86.

    Google Scholar 

  • Canitano, R. (2005). Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Development, 27(3), 228–232.

    PubMed  Google Scholar 

  • Ceranoglu, T. A., Wozniak, J., Fried, R., Galdo, M., Hoskova, B., DeLeon Fong, M., et al. (2019). A retrospective chart review of buspirone for the treatment of anxiety in psychiatrically referred youth with high-functioning autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 29(1), 28–33. https://doi.org/10.1089/cap.2018.0021.

    Article  PubMed Central  PubMed  Google Scholar 

  • Chez, M. G., Aimonovitch, M., Buchanan, T., Mrazek, S., & Tremb, R. J. (2004). Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of Child Neurology, 19(3), 165–169.

    PubMed  Google Scholar 

  • Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574–579.

    PubMed  Google Scholar 

  • Chugani, D. C., Chugani, H. T., Wiznitzer, M., Parikh, S., Evans, P. A., Hansen, R. L., … Autism Center of Excellence, N. (2016). Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: A randomized trial. Journal of Pediatrics, 170, 45–53 e41–44.

    Google Scholar 

  • Cohen, I. L., Campbell, M., Posner, D., Small, A. M., Triebel, D., & Anderson, L. T. (1980). Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design. Journal of the American Academy of Child Psychiatry, 19(4), 665–677.

    Google Scholar 

  • Conners, C. K., Casat, C. D., Gualtieri, C. T., Weller, E., Reader, M., Reiss, A., et al. (1996). Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry, 35(10), 1314–1321.

    PubMed  Google Scholar 

  • Corson, A. H., Barkenbus, J. E., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2004). A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. Journal of Clinical Psychiatry, 65(11), 1531–1536.

    PubMed  Google Scholar 

  • Coskun, M., Karakoc, S., Kircelli, F., & Mukaddes, N. M. (2009). Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 19(2), 203–206.

    PubMed  Google Scholar 

  • Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., et al. (2012). Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics, 130(Suppl 2), S69–76.

    PubMed  Google Scholar 

  • Crowley, B., Howe, Y. J., & McDougle, C. J. (2015). Topiramate for weight loss in two young adult women with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 25(2), 183–185.

    PubMed  Google Scholar 

  • Dadds, M. R., MacDonald, E., Cauchi, A., Williams, K., Levy, F., & Brennan, J. (2014). Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. Journal of Autism and Developmental Disorders, 44(3), 521–531.

    PubMed  Google Scholar 

  • Davanzo, P. A., Belin, T. R., Widawski, M. H., & King, B. H. (1998). Paroxetine treatment of aggression and self-injury in persons with mental retardation. American Journal of Mental Retardation, 102(5), 427–437.

    PubMed  Google Scholar 

  • DeLong, G. R., Ritch, C. R., & Burch, S. (2002). Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Developmental Medicine and Child Neurology, 44(10), 652–659.

    PubMed  Google Scholar 

  • Domes, G., Kumbier, E., Heinrichs, M., & Herpertz, S. C. (2014). Oxytocin promotes facial emotion recognition and amygdala reactivity in adults with asperger syndrome. Neuropsychopharmacology, 39(3), 698–706.

    PubMed  Google Scholar 

  • Dosman, C. F., Brian, J. A., Drmic, I. E., Senthilselvan, A., Harford, M. M., Smith, R. W., et al. (2007). Children with autism: effect of iron supplementation on sleep and ferritin. Pediatric Neurology, 36(3), 152–158.

    PubMed  Google Scholar 

  • Douglas, J. F., Sanders, K. B., Benneyworth, M. H., Smith, J. L., Dejean, V. M., McGrew, S. G., et al. (2013). Brief report: Retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder. Journal of Autism and Developmental Disorders, 43(5), 1243–1247.

    PubMed  Google Scholar 

  • Elchaar, G. M., Maisch, N. M., Augusto, L. M., & Wehring, H. J. (2006). Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Annals of Pharmacotherapy, 40(6), 1086–1095.

    PubMed  Google Scholar 

  • Erickson, C. A., Posey, D. J., Stigler, K. A., Mullett, J., Katschke, A. R., & McDougle, C. J. (2007). A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl), 191(1), 141–147.

    Google Scholar 

  • Fankhauser, M. P., Karumanchi, V. C., German, M. L., Yates, A., & Karumanchi, S. D. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 53(3), 77–82.

    PubMed  Google Scholar 

  • Farmer, C., Thurm, A., & Grant, P. (2013). Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. Drugs, 73(4), 303–314.

    PubMed Central  PubMed  Google Scholar 

  • Fatemi, S. H., Realmuto, G. M., Khan, L., & Thuras, P. (1998). Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. Journal of Autism and Developmental Disorders, 28(4), 303–307.

    PubMed  Google Scholar 

  • Feldman, H. M., Kolmen, B. K., & Gonzaga, A. M. (1999). Naltrexone and communication skills in young children with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 38(5), 587–593.

    PubMed  Google Scholar 

  • Findling, R. L., Mankoski, R., Timko, K., Lears, K., McCartney, T., McQuade, R. D., et al. (2014). A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry, 75(1), 22–30.

    PubMed  Google Scholar 

  • Findling, R. L., Maxwell, K., & Wiznitzer, M. (1997). An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacology Bulletin, 33(1), 155–159.

    PubMed  Google Scholar 

  • Findling, R. L., McNamara, N. K., Gracious, B. L., O’Riordan, M. A., Reed, M. D., Demeter, C., et al. (2004). Quetiapine in nine youths with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 14(2), 287–294.

    PubMed  Google Scholar 

  • Frazier, J. A., Biederman, J., Bellordre, C. A., Garfield, S. B., Geller, D. A., Coffey, B. J., et al. (2001). Should the diagnosis of attention-deficit/hyperactivity disorder be considered in children with pervasive developmental disorder? Journal of Attention Disorders, 4(4), 203–211.

    Google Scholar 

  • Frye, R. E. (2018). Social skills deficits in autism spectrum disorder: Potential biological origins and progress in developing therapeutic agents. CNS Drugs, 32(8), 713–734.

    PubMed Central  PubMed  Google Scholar 

  • Frye, R. E., & James, S. J. (2014). Metabolic pathology of autism in relation to redox metabolism. Biomarkers in Medicine, 8(3), 321–330.

    PubMed  Google Scholar 

  • Frye, R. E., Slattery, J., Delhey, L., Furgerson, B., Strickland, T., Tippett, M., et al. (2018). Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Molecular Psychiatry, 23(2), 247–256.

    PubMed  Google Scholar 

  • Fukuda, T., Sugie, H., Ito, M., & Sugie, Y. (2001). Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder. No To Hattatsu, 33(4), 314–318.

    PubMed  Google Scholar 

  • Garnock-Jones, K. P., & Keating, G. M. (2009). Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatric Drugs, 11(3), 203–226.

    PubMed  Google Scholar 

  • Gedye, A. (1991). Trazodone reduced aggressive and self-injurious movements in a mentally handicapped male patient with autism. Journal of Clinical Psychopharmacology, 11(4), 275–276.

    PubMed  Google Scholar 

  • Ghanizadeh, A., & Ayoobzadehshirazi, A. (2015). A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology, 52(1), 77–81.

    PubMed  Google Scholar 

  • Ghanizadeh, A., Sahraeizadeh, A., & Berk, M. (2014). A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development, 45(2), 185–192.

    PubMed  Google Scholar 

  • Giannotti, F., Cortesi, F., Cerquiglini, A., & Bernabei, P. (2006). An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. Journal of Autism and Developmental Disorders, 36(6), 741–752.

    PubMed  Google Scholar 

  • Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S. D., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50(6), 441–447.

    PubMed  Google Scholar 

  • Gordon, I., Vander Wyk, B. C., Bennett, R. H., Cordeaux, C., Lucas, M. V., Eilbott, J. A., et al. (2013). Oxytocin enhances brain function in children with autism. Proceedings of the National Academy of Sciences, 110(52), 20953–20958.

    Google Scholar 

  • Greenhill, L. L., Pliszka, S., Dulcan, M. K., Bernet, W., Arnold, V., Beitchman, J., et al. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 41(2 Suppl), 26S–49S.

    PubMed  Google Scholar 

  • Greist, J. H., Jefferson, J. W., Kobak, K. A., Katzelnick, D. J., & Serlin, R. C. (1995). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Archives of General Psychiatry, 52(1), 53–60.

    PubMed  Google Scholar 

  • Gringras, P., Nir, T., Breddy, J., Frydman-Marom, A., & Findling, R. L. (2017). Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 56(11), 948–957 e944.

    Google Scholar 

  • Guastella, A. J., Einfeld, S. L., Gray, K. M., Rinehart, N. J., Tonge, B. J., Lambert, T. J., et al. (2010). Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biological Psychiatry, 67(7), 692–694.

    PubMed  Google Scholar 

  • Guoynes, C. D., Simmons, T. C., Downing, G. M., Jacob, S., Solomon, M., & Bales, K. L. (2018). Chronic intranasal oxytocin has dose-dependent effects on central oxytocin and vasopressin systems in prairie voles (Microtus ochrogaster). Neuroscience, 369, 292–302.

    PubMed  Google Scholar 

  • Handen, B. L., Aman, M. G., Arnold, L. E., Hyman, S. L., Tumuluru, R. V., Lecavalier, L., et al. (2015). Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 54(11), 905–915.

    PubMed Central  PubMed  Google Scholar 

  • Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245–255.

    PubMed  Google Scholar 

  • Handen, B. L., Sahl, R., & Hardan, A. Y. (2008). Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics, 29(4), 303–308.

    PubMed  Google Scholar 

  • Hardan, A. Y., Jou, R. J., & Handen, B. L. (2005). Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 35(3), 387–391.

    PubMed  Google Scholar 

  • Harfterkamp, M., Buitelaar, J. K., Minderaa, R. B., van de Loo-Neus, G., van der Gaag, R. J., & Hoekstra, P. J. (2014). Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change. Journal of Child and Adolescent Psychopharmacology, 24(9), 481–485.

    PubMed  Google Scholar 

  • Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R. J., Escobar, R., Schacht, A., et al. (2012). A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51(7), 733–741.

    PubMed  Google Scholar 

  • Hartley-McAndrew, M., & Weinstock, A. (2010). Autism Spectrum Disorder: Correlation between aberrant behaviors. EEG abnormalities and seizures. Neurol Int, 2(1), e10.

    PubMed Central  PubMed  Google Scholar 

  • Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000). Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry, 57(5), 503–509.

    PubMed  Google Scholar 

  • Hazell, P. (2007). Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. Journal of Paediatric and Child Health, 43(1–2), 19–24.

    Google Scholar 

  • Hellings, J. A., Kelley, L. A., Gabrielli, W. F., Kilgore, E., & Shah, P. (1996). Sertraline response in adults with mental retardation and autistic disorder. Journal of Clinical Psychiatry, 57(8), 333–336.

    PubMed  Google Scholar 

  • Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., et al. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15(4), 682–692.

    PubMed  Google Scholar 

  • Herscu, P., Handen, B. L., Arnold, L. E., Snape, M. F., Bregman, J. D., Ginsberg, L., … Autism Speaks Autism Clinical Trials, N. (2019). The SOFIA Study: Negative multi-center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. Journal of Autism and Developmental Disorders.

    Google Scholar 

  • Hollander, E., Bartz, J., Chaplin, W., Phillips, A., Sumner, J., Soorya, L., et al. (2007). Oxytocin increases retention of social cognition in autism. Biological Psychiatry, 61(4), 498–503.

    PubMed  Google Scholar 

  • Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., et al. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35(4), 990–998.

    PubMed  Google Scholar 

  • Hollander, E., Dolgoff-Kaspar, R., Cartwright, C., Rawitt, R., & Novotny, S. (2001). An open trial of divalproex sodium in autism spectrum disorders. Journal of Clinical Psychiatry, 62(7), 530–534.

    PubMed  Google Scholar 

  • Hollander, E., Kaplan, A., Cartwright, C., & Reichman, D. (2000). Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. Journal of Child Neurology, 15(2), 132–135.

    PubMed  Google Scholar 

  • Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C. M., Aronowitz, B. R., et al. (2003). Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology, 28(1), 193–198.

    PubMed  Google Scholar 

  • Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., et al. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30(3), 582–589.

    PubMed  Google Scholar 

  • Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., et al. (2012). A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry, 169(3), 292–299.

    PubMed  Google Scholar 

  • Hollander, E., Soorya, L., Wasserman, S., Esposito, K., Chaplin, W., & Anagnostou, E. (2006a). Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology, 9(2), 209–213.

    Google Scholar 

  • Hollander, E., Wasserman, S., Swanson, E. N., Chaplin, W., Schapiro, M. L., Zagursky, K., et al. (2006b). A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology, 16(5), 541–548.

    PubMed  Google Scholar 

  • Horvath, K., Stefanatos, G., Sokolski, K. N., Wachtel, R., Nabors, L., & Tildon, J. T. (1998). Improved social and language skills after secretin administration in patients with autistic spectrum disorders. Journal of the Association for Academic Minority Physicians, 9(1), 9–15.

    PubMed  Google Scholar 

  • Huffman, L. C., Sutcliffe, T. L., Tanner, I. S., & Feldman, H. M. (2011). Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments. Journal of Developmental and Behavioral Pediatrics, 32(1), 56–68.

    PubMed  Google Scholar 

  • Hurwitz, R., Blackmore, R., Hazell, P., Williams, K., & Woolfenden, S. (2012). Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database Systematic Reviews, (3), CD008372.

    Google Scholar 

  • Ichikawa, H., Mikami, K., Okada, T., Yamashita, Y., Ishizaki, Y., Tomoda, A., et al. (2017). Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. Child Psychiatry and Human Development, 48(5), 796–806.

    PubMed  Google Scholar 

  • Jaselskis, C. A., Cook, E. H., Jr., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12(5), 322–327.

    PubMed  Google Scholar 

  • Ji, N., & Findling, R. L. (2015). An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Current Opinion in Psychiatry, 28(2), 91–101.

    PubMed  Google Scholar 

  • Joshi, G., Wozniak, J., Faraone, S. V., Fried, R., Chan, J., Furtak, S., et al. (2016). A prospective open-label trial of memantine hydrochloride for the treatment of social deficits in intellectually capable adults with autism spectrum disorder. Journal of Clinical Psychopharmacology, 36(3), 262–271.

    PubMed  Google Scholar 

  • Kelsey, J. E. (1996). Dose-response relationship with venlafaxine. Journal of Clinical Psychopharmacology, 16(3 Suppl 2), 21S-26S; discussion 26S-28S.

    Google Scholar 

  • Kem, D. L., Posey, D. J., & McDougle, C. J. (2002). Priapism associated with trazodone in an adolescent with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41(7), 758.

    PubMed  Google Scholar 

  • Kemner, C., Willemsen-Swinkels, S. H., de Jonge, M., Tuynman-Qua, H., & van Engeland, H. (2002). Open-label study of olanzapine in children with pervasive developmental disorder. Journal of Clinical Psychopharmacology, 22(5), 455–460.

    PubMed  Google Scholar 

  • Kent, J. M., Hough, D., Singh, J., Karcher, K., & Pandina, G. (2013). An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 23(10), 676–686.

    PubMed Central  PubMed  Google Scholar 

  • King, B. H. (2000). Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 30(5), 439–445.

    PubMed  Google Scholar 

  • King, B. H., & Davanzo, P. A. (1996). Buspirone treatment of aggression and self-injury in autistic and nonautistic persons with severe mental retardation. Developmental Brain Dysfunction, 90(1), 22–31.

    Google Scholar 

  • King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590.

    PubMed Central  PubMed  Google Scholar 

  • Kolmen, B. K., Feldman, H. M., Handen, B. L., & Janosky, J. E. (1995). Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry, 34(2), 223–231.

    PubMed  Google Scholar 

  • Lewitzka, U., Severus, E., Bauer, R., Ritter, P., Muller-Oerlinghausen, B., & Bauer, M. (2015). The suicide prevention effect of lithium: More than 20 years of evidence-a narrative review. International Journal of Bipolar Disorder, 3(1), 32.

    Google Scholar 

  • Loebel, A., Brams, M., Goldman, R. S., Silva, R., Hernandez, D., Deng, L., et al. (2016). Lurasidone for the treatment of irritability associated with autistic disorder. Journal of Autism and Developmental Disorders, 46(4), 1153–1163.

    PubMed  Google Scholar 

  • Malhi, G. S., Tanious, M., Das, P., Coulston, C. M., & Berk, M. (2013). Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs, 27(2), 135–153.

    PubMed  Google Scholar 

  • Malone, R. P., Cater, J., Sheikh, R. M., Choudhury, M. S., & Delaney, M. A. (2001). Olanzapine versus haloperidol in children with autistic disorder: An open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 40(8), 887–894.

    PubMed  Google Scholar 

  • Malone, R. P., Delaney, M. A., Hyman, S. B., & Cater, J. R. (2007). Ziprasidone in adolescents with autism: An open-label pilot study. Journal of Child and Adolescent Psychopharmacology, 17(6), 779–790.

    PubMed  Google Scholar 

  • Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121(3), e441–448.

    PubMed  Google Scholar 

  • Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119.

    PubMed  Google Scholar 

  • Marcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., et al. (2011). Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. Journal of Clinical Psychiatry, 72(9), 1270–1276.

    PubMed  Google Scholar 

  • Marrosu, F., Marrosu, G., Rachel, M. G., & Biggio, G. (1987). Paradoxical reactions elicited by diazepam in children with classic autism. Functional Neurology, 2(3), 355–361.

    PubMed  Google Scholar 

  • Marshall, B. L., Napolitano, D. A., McAdam, D. B., Dunleavy, I. J., Tessing, J. L., & Varrell, J. (2003). Venlafaxine and increased aggression in a female with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 42(4), 383–384.

    PubMed  Google Scholar 

  • Martin, A., Koenig, K., Anderson, G. M., & Scahill, L. (2003). Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders, 33(1), 77–85.

    PubMed  Google Scholar 

  • Martin, A., Koenig, K., Scahill, L., & Bregman, J. (1999). Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 9(2), 99–107.

    PubMed  Google Scholar 

  • Masi, G., Cosenza, A., Mucci, M., & Brovedani, P. (2001). Open trial of risperidone in 24 young children with pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 40(10), 1206–1214.

    PubMed  Google Scholar 

  • McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., … Research Units on Pediatric Psychopharmacology Autism. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321.

    Google Scholar 

  • McDougle, C. J., Brodkin, E. S., Naylor, S. T., Carlson, D. C., Cohen, D. J., & Price, L. H. (1998a). Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. Journal of Clinical Psychopharmacology, 18(1), 62–66.

    PubMed  Google Scholar 

  • McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998b). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry, 55(7), 633–641.

    PubMed  Google Scholar 

  • McDougle, C. J., Holmes, J. P., Bronson, M. R., Anderson, G. M., Volkmar, F. R., Price, L. H., et al. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 36(5), 685–693.

    PubMed  Google Scholar 

  • McDougle, C. J., Kem, D. L., & Posey, D. J. (2002). Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41(8), 921–927.

    PubMed  Google Scholar 

  • McDougle, C. J., Kresch, L. E., & Posey, D. J. (2000). Repetitive thoughts and behavior in pervasive developmental disorders: Treatment with serotonin reuptake inhibitors. Journal of Autism and Developmental Disorders, 30(5), 427–435.

    PubMed  Google Scholar 

  • McDougle, C. J., Naylor, S. T., Cohen, D. J., Aghajanian, G. K., Heninger, G. R., & Price, L. H. (1996a). Effects of tryptophan depletion in drug-free adults with autistic disorder. Archives of General Psychiatry, 53(11), 993–1000.

    PubMed  Google Scholar 

  • McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., & Price, L. H. (1996b). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53(11), 1001–1008.

    PubMed  Google Scholar 

  • McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162(6), 1142–1148.

    PubMed  Google Scholar 

  • McGuire, K., Fung, L. K., Hagopian, L., Vasa, R. A., Mahajan, R., Bernal, P., et al. (2016). Irritability and problem behavior in autism spectrum disorder: A practice pathway for pediatric primary care. Pediatrics, 137(Suppl 2), S136–148.

    PubMed  Google Scholar 

  • Meyer, J. M., Davis, V. G., Goff, D. C., McEvoy, J. P., Nasrallah, H. A., Davis, S. M., … Lieberman, J. A. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophrenia Research, 101(0), 273–286.

    Google Scholar 

  • Milin, R., Simeon, J. G., Batth, S., Thatte, S., Dare, G. J., & Walker, S. (2006). An open trial of olanzapine in children and adolescents with Asperger disorder. Journal of Clinical Psychopharmacology, 26(1), 90–92.

    PubMed  Google Scholar 

  • Ming, X., Gordon, E., Kang, N., & Wagner, G. C. (2008). Use of clonidine in children with autism spectrum disorders. Brain Development, 30(7), 454–460.

    PubMed  Google Scholar 

  • Minshawi, N. F., Wink, L. K., Shaffer, R., Plawecki, M. H., Posey, D. J., Liu, H., et al. (2016). A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism, 7, 2.

    PubMed Central  PubMed  Google Scholar 

  • Mintz, M., & Hollenberg, E. (2019). Revisiting lithium: Utility for behavioral stabilization in adolescents and adults with autism spectrum disorder. Psychopharmacology Bulletin, 49(2), 28–40.

    PubMed Central  PubMed  Google Scholar 

  • Munesue, T., Nakamura, H., Kikuchi, M., Miura, Y., Takeuchi, N., Anme, T., et al. (2016). Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: A randomized pilot study. Front Psychiatry, 7, 2.

    PubMed Central  PubMed  Google Scholar 

  • Nguyen, M., & Murphy, T. (2001). Mirtazapine for excessive masturbation in an adolescent with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 40(8), 868–869.

    PubMed  Google Scholar 

  • Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 37(4), 372–376.

    PubMed  Google Scholar 

  • Nicolson, R., Craven-Thuss, B., & Smith, J. (2006). A prospective, open-label trial of galantamine in autistic disorder. Journal of Child and Adolescent Psychopharmacology, 16(5), 621–629.

    PubMed  Google Scholar 

  • Ocakoglu, F. T., Kose, S., Ozbaran, B., & Onay, H. (2018). The oxytocin receptor gene polymorphism -rs237902- is associated with the severity of autism spectrum disorder: A pilot study. Asian Journal of Psychiatry, 31, 142–149.

    PubMed  Google Scholar 

  • Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533–1540.

    PubMed  Google Scholar 

  • Owley, T., Salt, J., Guter, S., Grieve, A., Walton, L., Ayuyao, N., et al. (2006). A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 517–524.

    PubMed  Google Scholar 

  • Owley, T., Walton, L., Salt, J., Guter, S. J., Jr., Winnega, M., Leventhal, B. L., et al. (2005). An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 44(4), 343–348.

    PubMed  Google Scholar 

  • Paavonen, E. J., Nieminen-von Wendt, T., Vanhala, R., Aronen, E. T., & von Wendt, L. (2003). Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. Journal of Child and Adolescent Psychopharmacology, 13(1), 83–95.

    PubMed  Google Scholar 

  • Panksepp, J., Najam, N., & Soares, F. (1979). Morphine reduces social cohesion in rats. Pharmacology and Biochemical Behavior, 11(2), 131–134.

    Google Scholar 

  • Parker, K. J., Oztan, O., Libove, R. A., Mohsin, N., Karhson, D. S., Sumiyoshi, R. D., … Hardan, A. Y. (2019). A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Science and Translational Medicine, 11(491).

    Google Scholar 

  • Pearson, D. A., Santos, C. W., Aman, M. G., Arnold, L. E., Casat, C. D., Mansour, R., et al. (2013). Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. Journal of Child and Adolescent Psychopharmacology, 23(5), 337–351.

    PubMed Central  PubMed  Google Scholar 

  • Perry, R., Campbell, M., Adams, P., Lynch, N., Spencer, E. K., Curren, E. L., et al. (1989). Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. Journal of the American Academy of Child and Adolescent Psychiatry, 28(1), 87–92.

    PubMed  Google Scholar 

  • Pizzarelli, R., & Cherubini, E. (2011). Alterations of GABAergic signaling in autism spectrum disorders. Neural Plastisity, 2011, 297153.

    Google Scholar 

  • Pliszka, S., & AACAP Work Group on Quality Issues. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46(7), 894–921.

    Google Scholar 

  • Posey, D. J., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2006). The use of selective serotonin reuptake inhibitors in autism and related disorders. Journal of Child and Adolescent Psychopharmacology, 16(1–2), 181–186.

    PubMed  Google Scholar 

  • Posey, D. J., Guenin, K. D., Kohn, A. E., Swiezy, N. B., & McDougle, C. J. (2001). A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 11(3), 267–277.

    PubMed  Google Scholar 

  • Posey, D. J., Kem, D. L., Swiezy, N. B., Sweeten, T. L., Wiegand, R. E., & McDougle, C. J. (2004a). A pilot study of D-cycloserine in subjects with autistic disorder. American Journal of Psychiatry, 161(11), 2115–2117.

    PubMed  Google Scholar 

  • Posey, D. J., Puntney, J. I., Sasher, T. M., Kem, D. L., & McDougle, C. J. (2004b). Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. Journal of Child and Adolescent Psychopharmacology, 14(2), 233–241.

    PubMed  Google Scholar 

  • Posey, D. J., Litwiller, M., Koburn, A., & McDougle, C. J. (1999). Paroxetine in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 38(2), 111–112.

    PubMed  Google Scholar 

  • Potenza, M. N., Holmes, J. P., Kanes, S. J., & McDougle, C. J. (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. Journal of Clinical Psychopharmacology, 19(1), 37–44.

    PubMed  Google Scholar 

  • Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., et al. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 25(3), 283–294.

    PubMed  Google Scholar 

  • Quintana, D. S., Westlye, L. T., Hope, S., Naerland, T., Elvsashagen, T., Dorum, E., et al. (2017). Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel breath powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial. Translational Psychiatry, 7(5), e1136.

    PubMed Central  PubMed  Google Scholar 

  • Ratey, J. J., Bemporad, J., Sorgi, P., Bick, P., Polakoff, S., O’Driscoll, G., et al. (1987). Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. Journal of Autism and Developmental Disorders, 17(3), 439–446.

    PubMed  Google Scholar 

  • Reilly, T. H., & Kirk, M. A. (2007). Atypical antipsychotics and newer antidepressants. Emergency Medicine Clinics of North America, 25(2), 477–497; abstract x.

    Google Scholar 

  • Remington, G., Sloman, L., Konstantareas, M., Parker, K., & Gow, R. (2001). Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology, 21(4), 440–444.

    PubMed  Google Scholar 

  • Research Units on Pediatric Psychopharmacology Autism, N. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274.

    Google Scholar 

  • Rezaei, V., Mohammadi, M. R., Ghanizadeh, A., Sahraian, A., Tabrizi, M., Rezazadeh, S. A., et al. (2010). Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuropsychopharmacology Biological Psychiatry, 34(7), 1269–1272.

    Google Scholar 

  • Richdale, A. L., & Schreck, K. A. (2009). Sleep problems in autism spectrum disorders: Prevalence, nature, & possible biopsychosocial aetiologies. Sleep Medicine Review, 13(6), 403–411.

    Google Scholar 

  • Rossignol, D. A., & Frye, R. E. (2011). Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Developmental Medicine and Child Neurology, 53(9), 783–792.

    PubMed  Google Scholar 

  • Rugino, T. A., & Samsock, T. C. (2002). Levetiracetam in autistic children: An open-label study. Journal of Developmental and Behavioral Pediatrics, 23(4), 225–230.

    PubMed  Google Scholar 

  • Sandman, C. A. (1988). Beta endorphin dysregulation in autistic and self injurious behaviour: A neurodevelopmental hypothesis. Synapse (New York, N.Y.), 2, 193–199.

    Google Scholar 

  • Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Dziura, J., et al. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589–598.

    PubMed  Google Scholar 

  • Scahill, L., Farkas, L., & Hamrin, V. (2001). Lithium in children and adolescents. Journal of Child and Adolescent Psychiatric Nursing, 14(2), 89–93.

    PubMed  Google Scholar 

  • Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., … Research Units on Pediatric Psychopharmacology Autism, N. (2015). Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. American Journal of Psychiatry, 172(12), 1197-1206.

    Google Scholar 

  • Schreck, K. A., Mulick, J. A., & Smith, A. F. (2004). Sleep problems as possible predictors of intensified symptoms of autism. Research in Developmental Disabilities, 25(1), 57–66.

    PubMed  Google Scholar 

  • Serret, S., Thummler, S., Dor, E., Vesperini, S., Santos, A., & Askenazy, F. (2015). Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: case reports. BMC Psychiatry, 15, 107.

    PubMed Central  PubMed  Google Scholar 

  • Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634–641.

    PubMed  Google Scholar 

  • Siegel, M., Beresford, C. A., Bunker, M., Verdi, M., Vishnevetsky, D., Karlsson, C., et al. (2014). Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 24(7), 399–402.

    PubMed  Google Scholar 

  • Sienaert, P., Dhossche, D. M., Vancampfort, D., De Hert, M., & Gazdag, G. (2014). A clinical review of the treatment of catatonia. Frontiers in Psychiatry, 5, 181.

    PubMed Central  PubMed  Google Scholar 

  • Smith, S. G., Gupta, K., & Smith, S. H. (1995). Effects of naltrexone on self-injury, stereotypy, and social behavior of adults with developmental disabilities. Journal of Developmental and Physical Disabilities, 7(2), 137–146.

    Google Scholar 

  • Snead, R. W., Boon, F., & Presberg, J. (1994). Paroxetine for self-injurious behavior. Journal of the American Academy of Child and Adolescent Psychiatry, 33(6), 909–910.

    PubMed  Google Scholar 

  • Spence, S. J., & Schneider, M. T. (2009). The role of epilepsy and epileptiform EEGs in autism spectrum disorders. Pediatric Research, 65(6), 599–606.

    PubMed Central  PubMed  Google Scholar 

  • Spencer, D., Marshall, J., Post, B., Kulakodlu, M., Newschaffer, C., Dennen, T., et al. (2013). Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics, 132(5), 833–840.

    PubMed Central  PubMed  Google Scholar 

  • Steenweg-de Graaff, J., Roza, S. J., Walstra, A. N., El Marroun, H., Steegers, E. A. P., Jaddoe, V. W. V., et al. (2017). Associations of maternal folic acid supplementation and folate concentrations during pregnancy with foetal and child head growth: The Generation R Study. European Journal of Nutrition, 56(1), 65–75.

    PubMed  Google Scholar 

  • Steingard, R. J., Zimnitzky, B., DeMaso, D. R., Bauman, M. L., & Bucci, J. P. (1997). Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 7(1), 9–15.

    PubMed  Google Scholar 

  • Stigler, K. A., Desmond, L. A., Posey, D. J., Wiegand, R. E., & McDougle, C. J. (2004a). A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14(1), 49–56.

    Google Scholar 

  • Stigler, K. A., Posey, D. J., & McDougle, C. J. (2004b). Aripiprazole for maladaptive behavior in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14(3), 455–463.

    Google Scholar 

  • Stigler, K. A., Mullett, J. E., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2012). Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl), 223(2), 237–245.

    Google Scholar 

  • Subcommittee on Attention-Deficit/Hyperactivity, D., Steering Committee on Quality, I., Management, Wolraich, M., Brown, L., Brown, R. T., … Visser, S. (2011). ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 128(5), 1007–1022.

    Google Scholar 

  • Sugie, Y., Sugie, H., Fukuda, T., Ito, M., Sasada, Y., Nakabayashi, M., et al. (2005). Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. Journal of Autism and Developmental Disorders, 35(3), 377–385.

    PubMed  Google Scholar 

  • Suren, P., Roth, C., Bresnahan, M., Haugen, M., Hornig, M., Hirtz, D., et al. (2013). Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA, 309(6), 570–577.

    PubMed Central  PubMed  Google Scholar 

  • Symons, F. J., Thompson, A., & Rodriguez, M. C. (2004). Self-injurious behavior and the efficacy of naltrexone treatment: A quantitative synthesis. Mental Retardation and Dvelopmental Disabilities Research Review, 10(3), 193–200.

    Google Scholar 

  • The Clomipramine Collaborative Study Group. (1991). Clomipramine in the treatment of patients with obsessive-compulsive disorder. Archives of General Psychiatry, 48(8), 730–738.

    Google Scholar 

  • Toichi, M., & Kamio, Y. (2003). Paradoxical autonomic response to mental tasks in autism. Journal of Autism and Developmental Disorders, 33(4), 417–426.

    PubMed  Google Scholar 

  • Urbano, M., Okwara, L., Manser, P., Hartmann, K., Herndon, A., & Deutsch, S. I. (2014). A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder. Clinical Neuropharmacology, 37(3), 69–72.

    PubMed Central  PubMed  Google Scholar 

  • Vahabzadeh, A., & McDougle, C. J. (2013). Maternal folic acid supplementation and risk of autism. JAMA, 309(21), 2208.

    PubMed  Google Scholar 

  • Valicenti-McDermott, M. R., & Demb, H. (2006). Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. Journal of Child and Adolescent Psychopharmacology, 16(5), 549–560.

    PubMed  Google Scholar 

  • Valicenti-McDermott, M., Lawson, K., Hottinger, K., Seijo, R., Schechtman, M., Shulman, L., et al. (2019). Sleep problems in children with autism and other developmental disabilities: A brief report. Journal of Child Neurology, 34(7), 387–393.

    PubMed  Google Scholar 

  • Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., et al. (2007). Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell, 129(2), 397–410.

    PubMed  Google Scholar 

  • Wang, Y., Wang, M., Rong, Y., He, H., & Yang, C. (2019). Oxytocin therapy for core symptoms in autism spectrum disorder: An updated meta-analysis of randomized controlled trials. Research in Autism Spectrum Disorders, 64, 63–75.

    Google Scholar 

  • Wasserman, S., Iyengar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostou, E., et al. (2006). Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study. International Journal of Clinical Psychopharmacology, 21(6), 363–367.

    Google Scholar 

  • Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., Iwashiro, N., et al. (2014). Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: A randomized trial. JAMA Psychiatry, 71(2), 166–175.

    PubMed  Google Scholar 

  • Watanabe, T., Otowa, T., Abe, O., Kuwabara, H., Aoki, Y., Natsubori, T., et al. (2017). Oxytocin receptor gene variations predict neural and behavioral response to oxytocin in autism. Social Cognitive and Affective Neuroscience, 12(3), 496–506.

    PubMed  Google Scholar 

  • Wilens, T. E., Adler, L. A., Adams, J., Sgambati, S., Rotrosen, J., Sawtelle, R., et al. (2008). Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry, 47(1), 21–31.

    PubMed  Google Scholar 

  • Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., et al. (2001). A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry, 158(2), 282–288.

    PubMed  Google Scholar 

  • Willemsen-Swinkels, S. H., Buitelaar, J. K., Nijhof, G. J., & van England, H. (1995a). Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Archives of General Psychiatry, 52(9), 766–773.

    Google Scholar 

  • Willemsen-Swinkels, S. H., Buitelaar, J. K., Weijnen, F. G., & van Engeland, H. (1995b). Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Research, 58(3), 203–215.

    PubMed  Google Scholar 

  • Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013). Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews, (8), CD004677.

    Google Scholar 

  • Williams, K. W., Wray, J. J., & Wheeler, D. M. (2005). Intravenous secretin for autism spectrum disorder. Cochrane Database of Systematic Reviews, (3), CD003495.

    Google Scholar 

  • Yamasue, H., Okada, T., Munesue, T., Kuroda, M., Fujioka, T., Uno, Y., … Kosaka, H. (2018). Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: A randomized clinical trial. Molecular Psychiatry.

    Google Scholar 

  • Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016). The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial. Molecular Psychiatry, 21(9), 1225–1231.

    PubMed  Google Scholar 

  • Zingarelli, G., Ellman, G., Hom, A., Wymore, M., Heidorn, S., & Chicz-DeMet, A. (1992). Clinical effects of naltrexone on autistic behavior. American Journal of Mental Retardation, 97(1), 57–63.

    PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by the Commonwealth of Massachusetts Department of Mental Health and Developmental Services and by the Nancy Lurie Marks family Foundation.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA

    Sirin Ozdemir

  2. Department of Psychiatry, Harvard Medical School, Lurie Center for Autism, Massachusetts General Hospital, Boston, MA, USA

    Christopher J. Keary & Christopher J. McDougle

  3. Department of Psychiatry, Bressler Clinical and Research Program for Autism Spectrum Disorders, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA

    Gagan Joshi & Atilla T. Ceranoglu

Authors
  1. Sirin Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. Keary
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gagan Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atilla T. Ceranoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher J. McDougle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sirin Ozdemir .

Editor information

Editors and Affiliations

  1. Department of Psychology, Utah State University, Logan, UT, USA

    Maryellen Brunson McClain

  2. Department of Psychiatry, University of Texas at Austin Dell Medical School, Austin, TX, USA

    Jeffrey D. Shahidullah

  3. Department of Educational Psychology, Miami University, Oxford, OH, USA

    Katherine R. Mezher

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ozdemir, S., Keary, C.J., Joshi, G., Ceranoglu, A.T., McDougle, C.J. (2020). Psychopharmacology of Autism Spectrum Disorder. In: McClain, M., Shahidullah, J., Mezher, K. (eds) Interprofessional Care Coordination for Pediatric Autism Spectrum Disorder. Springer, Cham. https://doi.org/10.1007/978-3-030-46295-6_25

Download citation

Publish with us

Policies and ethics

Search

Navigation